Previous preclinical work in ischaemic stroke has found that the BTK inhibitor ibrutinib inhibits IL-1β maturation and NLRP3 inflammasome activation in infiltrating macrophages and neutrophils in the infarct area of the MCAO model (Ito et al. 2015). This evidence concerns the gene IL1B and ischemic stroke.